Literature DB >> 2574239

Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells.

G J Schuurhuis1, H J Broxterman, A Cervantes, T H van Heijningen, J H de Lange, J P Baak, H M Pinedo, J Lankelma.   

Abstract

There is a large discrepancy between the changes in drug accumulation and the changes in drug cytotoxicity that accompany development of anthracycline resistance in multidrug-resistant cells. In our study, a quantitative relationship has been established between reversal of multidrug resistance by resistance modifiers and a concomitant decrease in intracellular levels of doxorubicin measured at equitoxic concentrations (IC50) in CHRC5 and 2780AD multidrug-resistant cells. (IC50 = concentration required for 50% growth inhibition.) We have demonstrated that resistance modifiers like verapamil and Ro 11-2933/001 act by increasing the effectiveness of intracellular doxorubicin, apparently by inducing redistribution of the drug from the cytoplasm to the nucleus of a multidrug-resistant cell, as shown by quantitative fluorescence microscopy. At complete reversal of resistance, as measured directly or inferred by extrapolation, the amount of intracellular doxorubicin at the IC50 as well as the ratio of nuclear doxorubicin to cytoplasmic doxorubicin were the same as those in sensitive cells. These results offer an explanation for the frequently observed discrepancies between drug accumulation and cytotoxicity and also show quantitatively that a decrease in drug accumulation and a change in intracellular drug distribution together are the only determinants of doxorubicin resistance in the multidrug-resistant cells studied.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2574239     DOI: 10.1093/jnci/81.24.1887

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  22 in total

1.  Intracellular distribution of anthracyclines in drug resistant cells.

Authors:  G Arancia; A Calcabrini; S Meschini; A Molinari
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

2.  Vault-related resistance to anticancer drugs determined by the expression of the major vault protein LRP.

Authors:  M A Izquierdo; G L Scheffer; A B Schroeijers; M C de Jong; R J Scheper
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

3.  Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study.

Authors:  Eisuke Kobayashi; Arun K Iyer; Francis J Hornicek; Mansoor M Amiji; Zhenfeng Duan
Journal:  Clin Orthop Relat Res       Date:  2013-03       Impact factor: 4.176

4.  Pharmacological and molecular characterization of intrinsic and acquired doxorubicin resistance in murine tumor cell lines.

Authors:  B Schott; D Londos-Gagliardi; C Ries; S Huet; J Robert
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

5.  Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma.

Authors:  Michiro Susa; Arun K Iyer; Keinosuke Ryu; Edwin Choy; Francis J Hornicek; Henry Mankin; Lara Milane; Mansoor M Amiji; Zhenfeng Duan
Journal:  PLoS One       Date:  2010-05-24       Impact factor: 3.240

6.  Digital cell image analysis of verapamil-induced effects in chemosensitive and chemoresistant neoplastic cell lines.

Authors:  C Etiévant; O Pauwels; R Kiss
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

7.  Reversal of multidrug resistance in Friend leukemia cells by dexniguldipine-HCl.

Authors:  A Reymann; G Looft; C Woermann; M Dietel; R Erttmann
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Effects of verapamil on the pharmacokinetics and metabolism of epirubicin.

Authors:  K Mross; K Hamm; D K Hossfeld
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 9.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

10.  Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma.

Authors:  Michiro Susa; Arun K Iyer; Keinosuke Ryu; Francis J Hornicek; Henry Mankin; Mansoor M Amiji; Zhenfeng Duan
Journal:  BMC Cancer       Date:  2009-11-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.